Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study

Science

Volumn 279, Issue 5350, 1998, Pages 563-566

  Chan, June M ^a   Stampfer, Meir J ^a   Giovannucci, Edward ^b   Gann, Peter H ^c   Ma, Jing ^b   Wilkinson, Peter ^d   Hennekens, Charles H ^b   Pollak, Michael ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ARTICLE; CANCER RISK; CELL PROLIFERATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DISEASE SUSCEPTIBILITY; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; REGRESSION ANALYSIS; RISK; RISK FACTORS;

EID: 0032559272     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5350.563     Document Type: Article

References (35)

1. S. M. Cohen and L. B. Ellwein, Science 249, 1007 (1990).
2. P. Cohen, D. M. Peehl, R. G. Rosenfeld, Hormone Metab. Res. 26, 81 (1994).
3. P. Cohen, D. M. Peehl, G. Lamson, R. G. Rosenfeld, J. Clin. Endocrinol. Metab. 73, 401 (1991).
4. R. Rajah, B. Valentinis, P. Cohen, J. Biol. Chem. 272, 12181 (1997).
5. J. I. Jones and D. R. Clemmons, Endocr. Rev. 16, 3 (1995).
6. A. Juul et al., J. Clin. Endocrinol. Metab. 78, 744 (1994).
7. A. Juul et al., ibid. 80, 2534 (1995).
8. Acromegaly and GH deficiency are examples where changes in tissues are correlated with serum IGF-I levels, implying a relation between serum IGF-I levels and tissue IGF-I bioactivity.
9. M. Pollak et al., J. Natl. Cancer Inst. 82, 1693 (1990).
10. H. Huynh, X. Yang, M. Pollak, J. Biol. Chem. 271, 1016 (1996).
11. H. Huynh, X. Yang, M. Pollak, Cell Growth Differ. 7, 1501 (1996).
12. Steering Committee of the Physicians' Health Study Research Group, N. Engl. J. Med. 321, 129 (1989). The Physicians' Health Study began in 1982 as a randomized, double-blinded, placebo-controlled trial of β-carotene and aspirin in 22,017 U.S. male physicians aged 40 to 82 without prior diagnosed cardiovascular disease or cancer. Each participant provided informed consent. Before randomization, the men had their blood drawn into vacutainer tubes containing EDTA (anti-coagulant). The blood was centrifuged and returned in polypropylene cryopreservation vials by overnight prepaid courier with cold packs to keep it cool. Upon receipt, the plasma was stored at -82°C. No specimen thawed or warmed substantially during storage.
13. The Whitmore-Jewett classification scheme was used to identify stage, and cases without pathological staging were considered indeterminate, unless there was evidence of metastases. Cases presenting as stage C or D were considered "high grade/ stage cancer." Also, we assigned that category to stage A, B, or indeterminate cases with either poor histological differentiation or a Gleason score of 7 or higher.
14. P. H. Gann, C. H. Hennekens, J. Ma, C. Longcope, M. J. Stampfer, J. Natl. Cancer Inst. 88, 1118 (1996).
15. P. H. Gann, C. H. Hennekens, M. J. Stampfer, J. Am. Med. Assoc. 273, 289 (1995).
16. E. Giovannucci et al., Proc. Natl. Acad. Sci. U.S.A. 94, 3320 (1997).
17. Selection bias is minimal here as it is unlikely that subjects returned blood samples or provided adequate blood volume differentially on the basis of any relation between their IGF levels in 1982 and later development of prostate cancer. Previous study has shown that cases who did and did not provide blood samples were not appreciably different in their baseline lifestyle characteristics (15).
18. The IGF-I values obtained by the ELISA were highly correlated (Pearson r = 0.97) with values obtained by radioimmunoassay after acid chromatography. All assays were carried out in a blinded manner, and quality control samples were included within assay runs. Average intra-assay coefficients of variation for IGF-I, IGF-II, and IGFBP-3 were 4.9%, 3.0%, and 9.0%, respectively.
19. To evaluate the effect of our blood collection methods on IGF-I levels, we compared IGF-I and IGFBP-3 levels in blood samples that were processed and serum frozen immediately after venipuncture (the usual collection and processing methods) to samples that were stored as heparinized whole blood for 24 and 36 hours before processing (mimicking our collection conditions). The mean IGF-I and IGFBP-3 values were almost identical and the interclass correlations between results of the two collection methods were 0.98 for IGF-I and 0.96 for IGFBP-3, indicating that our collection methods did not adversely affect sample integrity.
20. To examine how well a single measurement of IGF-I represents levels over time, we collected two blood samples each from 16 people, 8 weeks apart (time 1 and time 2). The correlation between blood levels taken at time 1 and time 2 was 0.65.
21. D. Goodman-Gruen and E. Barrett-Connor, Am. J. Epidemiol. 145, 970 (1997).
22. E. Giovannucci, E. B. Rimm, M. J. Stampfer, G. A. Colditz, W. C. Willett, Cancer Epidemiol. Biomarkers Prev. 6, 557 (1997).
23. S.-O. Andersson et al., J. Natl. Cancer Inst. 89, 385 (1997).
24. K. J. Rothman, Modern Epidemiology (Little, Brown, Boston, MA, 1986), pp. 82-97 and 286-310.
25. M. M. Rechler, Endocrinology 138, 2645 (1997).
26. P. Cohen et al., J. Clin. Endocrinol. Metab. 75, 1046 (1992).
27. C. S. Mantzoros et al., Br. J. Cancer 76, 1115 (1997).
28. C. La Vecchia et al., Int. J. Cancer 45, 275 (1990).
29. P. R. Hebert et al., Cancer Causes Control 8, 591 (1997).
30. G. Tibllin, M. Eriksoon, S. Cnattingius, A. Ekbom, Epidemiology 6, 423 (1995).
31. C. Lassarre et al., Pediatr. Res. 29, 219 (1991).
32. M. Pollak and A. Schally, Proc. Soc. Exp. Biol. Med. 217, 143 (1998).
33. M. Zarandi et al., Proc. Natl. Acad. Sci. U.S.A. 91, 12298 (1994).
34. D. Rudman et al., N. Engl. J. Med. 323, 1 (1990).
35. Supported by National Research Service Award 5 T32 CA 09001-20, National Cancer Institute grants CA-58684 and CA-42182, and the National Cancer Institute of Canada.